On the clinical usefulness of the free-to-total prostate-specific antigen ratio

International Journal of Biological Markers

Volumn 21, Issue 1, 2006, Pages 1-5

  Ciatto, S ^a   Rubeca, T ^a   Franceschini, R ^b   Trevisiol, C ^b   Confortini, M ^a   Pontenani, G ^a   Lombardi, C ^a  

^a Center for the Study and Prevention of Oncology   (Italy)

^b Venice Hospital   (Italy)

Author keywords

F T PSA ratio; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRANSRECTAL ULTRASONOGRAPHY;

EID: 33646172567     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3846     Document Type: Review

References (17)

1. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am 1993; 20: 671-80.
2. Ciatto S, Bonardi R, Mazzotta A, Santoni R. Reliability of volume or age-adjusted prostate specific antigen to improve diagnostic accuracy. Int J Biol Markers 1995; 10: 226-8.
3. Ciatto S, Bonardi R, Lombardi C, et al. Predicting prostate biopsy outcome by findings at digital rectal examination, transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a population-based screening setting. Int J Biol Markers 2001; 16: 179-82.
4. Benson KC, Wang IS, Olsson CA. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen, J Urol 1992; 147: 817-21.
5. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20.
6. Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G, Cappelli G. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. Int J Biol Markers 2002; 17: 79-83.
7. Lilja H, Bjork T, Abrahamsson PA. Improved separations between normals, benign prostatic hyperplasia and carcinoma of the prostate by measuring free, complexed and total concentrations of prostate specific antigen, J Urol 1994; 151: 400A.
8. Catalona WG, Smith S, Wolfer RL. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20.
9. Oesterling JE, Jacobsen SJ, Klee GG. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentration and ratios. J Urol 1995; 154: 1090-5.
10. Vis NA, Boerma MO, Ciatto S, Hoedemaeker RF, Schroeder FH, van der Kwast T. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 2000; 56: 617-21.
11. Egger M, Davey Smith G, O'Rouke K. Rationale, potentials, and promise of systematic reviews. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care. London: BMJ Publishing Group, 2001.
12. Hoffman RM, Clanon DL, Littenberg B, Frank JJ, Peirce JC. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med 2000; 15: 739-48.
13. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005; 48: 386-99.
14. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-12.
15. Eskew LA, Bare RL, McCulloch DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-203.
16. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78.
17. Ciatto S, Gervasi G, Bonardi R, et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 2005; 41: 411-5.